Click here to get full coverage on Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.3% - What's Next? - MarketBeat

Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.3% - What's Next?  MarketBeat

Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.3% - What's Next? - MarketBeat

Click here to get full coverage on Leads Biolabs and DNTH initiate trial of LBL-047 in SLE - Clinical Trials Arena

Leads Biolabs and DNTH initiate trial of LBL-047 in SLE  Clinical Trials Arena

Leads Biolabs and DNTH initiate trial of LBL-047 in SLE - Clinical Trials Arena

Click here to get full coverage on First Week of August 2026 Options Trading For Dianthus Therapeutics (DNTH) - Nasdaq

First Week of August 2026 Options Trading For Dianthus Therapeutics (DNTH)  Nasdaq

First Week of August 2026 Options Trading For Dianthus Therapeutics (DNTH) - Nasdaq

Click here to get full coverage on Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential - Yahoo Finance

Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential  Yahoo Finance

Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential - Yahoo Finance

Click here to get full coverage on Dianthus Therapeutics, Inc. $DNTH Stake Lessened by Moody Aldrich Partners LLC - MarketBeat

Dianthus Therapeutics, Inc. $DNTH Stake Lessened by Moody Aldrich Partners LLC  MarketBeat

Dianthus Therapeutics, Inc. $DNTH Stake Lessened by Moody Aldrich Partners LLC - MarketBeat

Click here to get full coverage on Dianthus Therapeutics Stock (DNTH) Opinions on Recent Price Surge and Clinical Trial Results | DNTH Stock News - Quiver Quantitative

Dianthus Therapeutics Stock (DNTH) Opinions on Recent Price Surge and Clinical Trial Results | DNTH Stock News  Quiver Quantitative

Dianthus Therapeutics Stock (DNTH) Opinions on Recent Price Surge and Clinical Trial Results | DNTH Stock News - Quiver Quantitative

Click here to get full coverage on Dianthus Therapeutics (DNTH): Valuation Check After Phase 1 LBL-047 Trial Kicks Off - simplywall.st

Dianthus Therapeutics (DNTH): Valuation Check After Phase 1 LBL-047 Trial Kicks Off  simplywall.st

Dianthus Therapeutics (DNTH): Valuation Check After Phase 1 LBL-047 Trial Kicks Off - simplywall.st

Click here to get full coverage on New lupus drug test begins, aiming for simple self-injections every month - Stock Titan

New lupus drug test begins, aiming for simple self-injections every month  Stock Titan

New lupus drug test begins, aiming for simple self-injections every month - Stock Titan

Click here to get full coverage on How Magenta Therapeutics Inc. (DNTH) Affects Rotational Strategy Timing - Stock Traders Daily

How Magenta Therapeutics Inc. (DNTH) Affects Rotational Strategy Timing  Stock Traders Daily

How Magenta Therapeutics Inc. (DNTH) Affects Rotational Strategy Timing - Stock Traders Daily

Click here to get full coverage on Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy?  Yahoo Finance

Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $DNTH Given $46 Price Target - Quiver Quantitative

New Analyst Forecast: $DNTH Given $46 Price Target  Quiver Quantitative

New Analyst Forecast: $DNTH Given $46 Price Target - Quiver Quantitative

Click here to get full coverage on Breaking: Biotech Dianthus Ready to Unveil Critical Phase 2 Results for Novel Autoimmune Drug Claseprubart - Stock Titan

Breaking: Biotech Dianthus Ready to Unveil Critical Phase 2 Results for Novel Autoimmune Drug Claseprubart  Stock Titan

Breaking: Biotech Dianthus Ready to Unveil Critical Phase 2 Results for Novel Autoimmune Drug Claseprubart - Stock Titan

Click here to get full coverage on Evaluating Dianthus Therapeutics (DNTH) Valuation After New DNTH212 Licensing Deal and Pipeline Expansion - Yahoo Finance

Evaluating Dianthus Therapeutics (DNTH) Valuation After New DNTH212 Licensing Deal and Pipeline Expansion  Yahoo Finance

Evaluating Dianthus Therapeutics (DNTH) Valuation After New DNTH212 Licensing Deal and Pipeline Expansion - Yahoo Finance

Click here to get full coverage on Wedbush Reiterates Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat

Wedbush Reiterates Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH)  MarketBeat

Wedbush Reiterates Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat

Click here to get full coverage on $251 Million Capital Raise: Dianthus Therapeutics Secures Major Funding for Autoimmune Drug Development - Stock Titan

$251 Million Capital Raise: Dianthus Therapeutics Secures Major Funding for Autoimmune Drug Development  Stock Titan

$251 Million Capital Raise: Dianthus Therapeutics Secures Major Funding for Autoimmune Drug Development - Stock Titan

Click here to get full coverage on Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates  Yahoo Finance

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on $150 Million Stock Offering: Biotech Dianthus Therapeutics Raises Funds for Autoimmune Drug Development - Stock Titan

$150 Million Stock Offering: Biotech Dianthus Therapeutics Raises Funds for Autoimmune Drug Development  Stock Titan

$150 Million Stock Offering: Biotech Dianthus Therapeutics Raises Funds for Autoimmune Drug Development - Stock Titan

Click here to get full coverage on Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum - Yahoo Finance

Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum  Yahoo Finance

Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum - Yahoo Finance

Click here to get full coverage on Dianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity Raise - Yahoo Finance

Dianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity Raise  Yahoo Finance

Dianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity Raise - Yahoo Finance

Click here to get full coverage on Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target - Yahoo Finance

Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target  Yahoo Finance

Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target - Yahoo Finance

Click here to get full coverage on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Brokerages  MarketBeat

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Click here to get full coverage on $288 Million Biotech Raise: Dianthus Therapeutics Completes Major Public Offering for Autoimmune Programs - Stock Titan

$288 Million Biotech Raise: Dianthus Therapeutics Completes Major Public Offering for Autoimmune Programs  Stock Titan

$288 Million Biotech Raise: Dianthus Therapeutics Completes Major Public Offering for Autoimmune Programs - Stock Titan

Click here to get full coverage on IND Cleared Sept 2025 — Dianthus In‑Licenses DNTH212 with $30M Upfront; Phase 1 to Start Q4'25 - Stock Titan

IND Cleared Sept 2025 — Dianthus In‑Licenses DNTH212 with $30M Upfront; Phase 1 to Start Q4'25  Stock Titan

IND Cleared Sept 2025 — Dianthus In‑Licenses DNTH212 with $30M Upfront; Phase 1 to Start Q4'25 - Stock Titan

Click here to get full coverage on Dianthus Therapeutics, Inc. $DNTH Shares Sold by 5AM Venture Management LLC - MarketBeat

Dianthus Therapeutics, Inc. $DNTH Shares Sold by 5AM Venture Management LLC  MarketBeat

Dianthus Therapeutics, Inc. $DNTH Shares Sold by 5AM Venture Management LLC - MarketBeat

Click here to get full coverage on Both 300mg and 600mg Doses Show Rapid Improvement: Dianthus's Claseprubart Succeeds in Phase 2 gMG Study - Stock Titan

Both 300mg and 600mg Doses Show Rapid Improvement: Dianthus's Claseprubart Succeeds in Phase 2 gMG Study  Stock Titan

Both 300mg and 600mg Doses Show Rapid Improvement: Dianthus's Claseprubart Succeeds in Phase 2 gMG Study - Stock Titan

Click here to get full coverage on Insider Sale: CFO & CBO of $DNTH Sells 20,000 Shares - Quiver Quantitative

Insider Sale: CFO & CBO of $DNTH Sells 20,000 Shares  Quiver Quantitative

Insider Sale: CFO & CBO of $DNTH Sells 20,000 Shares - Quiver Quantitative

Click here to get full coverage on Notable Wednesday Option Activity: ISRG, DNTH, CNR - Nasdaq

Notable Wednesday Option Activity: ISRG, DNTH, CNR  Nasdaq

Notable Wednesday Option Activity: ISRG, DNTH, CNR - Nasdaq

Click here to get full coverage on New Analyst Forecast: $DNTH Given 'Buy' Rating - Quiver Quantitative

New Analyst Forecast: $DNTH Given 'Buy' Rating  Quiver Quantitative

New Analyst Forecast: $DNTH Given 'Buy' Rating - Quiver Quantitative

Click here to get full coverage on 27,003 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by XTX Topco Ltd - MarketBeat

27,003 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by XTX Topco Ltd  MarketBeat

27,003 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by XTX Topco Ltd - MarketBeat

Click here to get full coverage on New Analyst Forecast: $DNTH Given $40.0 Price Target - Quiver Quantitative

New Analyst Forecast: $DNTH Given $40.0 Price Target  Quiver Quantitative

New Analyst Forecast: $DNTH Given $40.0 Price Target - Quiver Quantitative

Click here to get full coverage on Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - Here's Why - MarketBeat

Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - Here's Why  MarketBeat

Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - Here's Why - MarketBeat

Click here to get full coverage on Dianthus Therapeutics (Nasdaq: DNTH) joins 8th Evercore Healthcare Conference on Dec. 2 - Stock Titan

Dianthus Therapeutics (Nasdaq: DNTH) joins 8th Evercore Healthcare Conference on Dec. 2  Stock Titan

Dianthus Therapeutics (Nasdaq: DNTH) joins 8th Evercore Healthcare Conference on Dec. 2 - Stock Titan

Click here to get full coverage on New Analyst Forecast: $DNTH Given $46.0 Price Target - Quiver Quantitative

New Analyst Forecast: $DNTH Given $46.0 Price Target  Quiver Quantitative

New Analyst Forecast: $DNTH Given $46.0 Price Target - Quiver Quantitative

Click here to get full coverage on Dianthus (NASDAQ: DNTH) advances CAPTIVATE interim to Q2 2026 on faster enrollment - Stock Titan

Dianthus (NASDAQ: DNTH) advances CAPTIVATE interim to Q2 2026 on faster enrollment  Stock Titan

Dianthus (NASDAQ: DNTH) advances CAPTIVATE interim to Q2 2026 on faster enrollment - Stock Titan

Click here to get full coverage on Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again - Investor's Business Daily

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again  Investor's Business Daily

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again - Investor's Business Daily

Click here to get full coverage on Dianthus Therapeutics Announces Conference Call to Discuss Phase 2 MaGic Trial Results for Claseprubart in Generalized Myasthenia Gravis - Quiver Quantitative

Dianthus Therapeutics Announces Conference Call to Discuss Phase 2 MaGic Trial Results for Claseprubart in Generalized Myasthenia Gravis  Quiver Quantitative

Dianthus Therapeutics Announces Conference Call to Discuss Phase 2 MaGic Trial Results for Claseprubart in Generalized Myasthenia Gravis - Quiver Quantitative

Click here to get full coverage on Leads Biolabs joins a $1B development deal with Dianthus - BioWorld MedTech

Leads Biolabs joins a $1B development deal with Dianthus  BioWorld MedTech

Leads Biolabs joins a $1B development deal with Dianthus - BioWorld MedTech

Click here to get full coverage on Dianthus Therapeutics stock soars after positive Phase 2 gMG trial data - Investing.com

Dianthus Therapeutics stock soars after positive Phase 2 gMG trial data  Investing.com

Dianthus Therapeutics stock soars after positive Phase 2 gMG trial data - Investing.com

Click here to get full coverage on Dianthus Therapeutics closes $288 million public offering - Investing.com

Dianthus Therapeutics closes $288 million public offering  Investing.com

Dianthus Therapeutics closes $288 million public offering - Investing.com

Click here to get full coverage on Dianthus to license autoimmune disease candidate in a deal worth up to $1B (DNTH:NASDAQ) - Seeking Alpha

Dianthus to license autoimmune disease candidate in a deal worth up to $1B (DNTH:NASDAQ)  Seeking Alpha

Dianthus to license autoimmune disease candidate in a deal worth up to $1B (DNTH:NASDAQ) - Seeking Alpha

Click here to get full coverage on Dianthus therapeutics EVP Randhawa sells $7.3m in shares - Investing.com

Dianthus therapeutics EVP Randhawa sells $7.3m in shares  Investing.com

Dianthus therapeutics EVP Randhawa sells $7.3m in shares - Investing.com

Click here to get full coverage on Dianthus Therapeutics stock maintains Buy rating at Guggenheim after licensing deal - Investing.com

Dianthus Therapeutics stock maintains Buy rating at Guggenheim after licensing deal  Investing.com

Dianthus Therapeutics stock maintains Buy rating at Guggenheim after licensing deal - Investing.com

Click here to get full coverage on Dianthus Therapeutics stock rating reiterated by TD Cowen after license deal - Investing.com

Dianthus Therapeutics stock rating reiterated by TD Cowen after license deal  Investing.com

Dianthus Therapeutics stock rating reiterated by TD Cowen after license deal - Investing.com

Click here to get full coverage on Dianthus Therapeutics stock maintains Buy rating at H.C. Wainwright - Investing.com

Dianthus Therapeutics stock maintains Buy rating at H.C. Wainwright  Investing.com

Dianthus Therapeutics stock maintains Buy rating at H.C. Wainwright - Investing.com

Click here to get full coverage on (DNTH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

(DNTH) Movement Within Algorithmic Entry Frameworks  Stock Traders Daily

(DNTH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Click here to get full coverage on Dianthus Therapeutics prices upsized public offering at $251 million - Investing.com

Dianthus Therapeutics prices upsized public offering at $251 million  Investing.com

Dianthus Therapeutics prices upsized public offering at $251 million - Investing.com

Click here to get full coverage on Dianthus Therapeutics stock price target raised to $60 by Oppenheimer - Investing.com

Dianthus Therapeutics stock price target raised to $60 by Oppenheimer  Investing.com

Dianthus Therapeutics stock price target raised to $60 by Oppenheimer - Investing.com

Click here to get full coverage on Behavioral Patterns of DNTH and Institutional Flows - Stock Traders Daily

Behavioral Patterns of DNTH and Institutional Flows  Stock Traders Daily

Behavioral Patterns of DNTH and Institutional Flows - Stock Traders Daily

Click here to get full coverage on Dianthus Therapeutics Reports Positive Phase 2 MaGic Trial Data for Claseprubart in Generalized Myasthenia Gravis and Plans Phase 3 Trial Initiation in 2026 - Quiver Quantitative

Dianthus Therapeutics Reports Positive Phase 2 MaGic Trial Data for Claseprubart in Generalized Myasthenia Gravis and Plans Phase 3 Trial Initiation in 2026  Quiver Quantitative

Dianthus Therapeutics Reports Positive Phase 2 MaGic Trial Data for Claseprubart in Generalized Myasthenia Gravis and Plans Phase 3 Trial Initiation in 2026 - Quiver Quantitative

Click here to get full coverage on Stocks Showing Market Leadership: Dianthus Therapeutics Earns 91 RS Rating - Investor's Business Daily

Stocks Showing Market Leadership: Dianthus Therapeutics Earns 91 RS Rating  Investor's Business Daily

Stocks Showing Market Leadership: Dianthus Therapeutics Earns 91 RS Rating - Investor's Business Daily

Click here to get full coverage on Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead - Seeking Alpha

Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead  Seeking Alpha

Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead - Seeking Alpha

Click here to get full coverage on Dianthus Therapeutics stock hits 52-week high at 38.65 USD - Investing.com

Dianthus Therapeutics stock hits 52-week high at 38.65 USD  Investing.com

Dianthus Therapeutics stock hits 52-week high at 38.65 USD - Investing.com

Click here to get full coverage on A Dive Into Dianthus Therapeutics: Little To Move The Stock (NASDAQ:DNTH) - Seeking Alpha

A Dive Into Dianthus Therapeutics: Little To Move The Stock (NASDAQ:DNTH)  Seeking Alpha

A Dive Into Dianthus Therapeutics: Little To Move The Stock (NASDAQ:DNTH) - Seeking Alpha

Click here to get full coverage on Dianthus to take gMG mAb to Phase III after mid-stage win - Yahoo Finance

Dianthus to take gMG mAb to Phase III after mid-stage win  Yahoo Finance

Dianthus to take gMG mAb to Phase III after mid-stage win - Yahoo Finance

Click here to get full coverage on William Blair Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating - 富途牛牛

William Blair Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating  富途牛牛

William Blair Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating - 富途牛牛

Click here to get full coverage on Dianthus Therapeutics Enters Into Exclusive DNTH212 Licensing Deal With Nanjing Leads Biolabs - Nasdaq

Dianthus Therapeutics Enters Into Exclusive DNTH212 Licensing Deal With Nanjing Leads Biolabs  Nasdaq

Dianthus Therapeutics Enters Into Exclusive DNTH212 Licensing Deal With Nanjing Leads Biolabs - Nasdaq

Click here to get full coverage on Dianthus Therapeutics stock hits 52-week high at 43.69 USD - Investing.com

Dianthus Therapeutics stock hits 52-week high at 43.69 USD  Investing.com

Dianthus Therapeutics stock hits 52-week high at 43.69 USD - Investing.com

Click here to get full coverage on Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors, Announces Transition of Lonnie Moulder - Quiver Quantitative

Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors, Announces Transition of Lonnie Moulder  Quiver Quantitative

Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors, Announces Transition of Lonnie Moulder - Quiver Quantitative

Click here to get full coverage on The Insider Report: Prepare for the Next Dip Buying Opportunity - Benzinga

The Insider Report: Prepare for the Next Dip Buying Opportunity  Benzinga

The Insider Report: Prepare for the Next Dip Buying Opportunity - Benzinga

Click here to get full coverage on Dianthus Therapeutics stock price target raised to $47 at H.C. Wainwright on positive trial data - Investing.com

Dianthus Therapeutics stock price target raised to $47 at H.C. Wainwright on positive trial data  Investing.com

Dianthus Therapeutics stock price target raised to $47 at H.C. Wainwright on positive trial data - Investing.com

Click here to get full coverage on Dianthus Therapeutics Reports Positive Phase 2 Results - TipRanks

Dianthus Therapeutics Reports Positive Phase 2 Results  TipRanks

Dianthus Therapeutics Reports Positive Phase 2 Results - TipRanks

Click here to get full coverage on Dianthus Therapeutics stock hits 52-week high at 40.4 USD - Investing.com

Dianthus Therapeutics stock hits 52-week high at 40.4 USD  Investing.com

Dianthus Therapeutics stock hits 52-week high at 40.4 USD - Investing.com

Click here to get full coverage on Check out Dianthus Therapeutics's stock price (DNTH) in real time - CNBC

Check out Dianthus Therapeutics's stock price (DNTH) in real time  CNBC

Check out Dianthus Therapeutics's stock price (DNTH) in real time - CNBC

Click here to get full coverage on Dianthus Therapeutics (DNTH): AI-Determined “Top Stock” Pick - The Globe and Mail

Dianthus Therapeutics (DNTH): AI-Determined “Top Stock” Pick  The Globe and Mail

Dianthus Therapeutics (DNTH): AI-Determined “Top Stock” Pick - The Globe and Mail

Click here to get full coverage on Dianthus: Modest Opportunity With 2 Caveats (NASDAQ:DNTH) - Seeking Alpha

Dianthus: Modest Opportunity With 2 Caveats (NASDAQ:DNTH)  Seeking Alpha

Dianthus: Modest Opportunity With 2 Caveats (NASDAQ:DNTH) - Seeking Alpha

Click here to get full coverage on Dianthus Therapeutics: Complement System Candidate Not Sufficiently Derisked - Seeking Alpha

Dianthus Therapeutics: Complement System Candidate Not Sufficiently Derisked  Seeking Alpha

Dianthus Therapeutics: Complement System Candidate Not Sufficiently Derisked - Seeking Alpha

Click here to get full coverage on Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference - Stock Titan

Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference  Stock Titan

DNTH

Price Chart

Key Statistics

Technicals

About DNTH

Latest News

Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.3% - What's Next? - MarketBeat

Leads Biolabs and DNTH initiate trial of LBL-047 in SLE - Clinical Trials Arena

First Week of August 2026 Options Trading For Dianthus Therapeutics (DNTH) - Nasdaq

Advanced Charts

Top Gainers

Top Losers